A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The New England journal of medicine
- Publicado em
- 25 jun 2026
- Citações
- 6
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
Francesca Conradie, Tasnim Badat, Asanda Poswa, Shakira Rajaram, Shaneen Kooverjee, Gary Maartens, Graeme Meintjes, Jennifer Hughes, H Simon Schaaf, Pauline Howell et al.
Descritores MeSH
- Tuberculosis, Pulmonary
- Antitubercular Agents
- Pregnancy Complications, Infectious
- Tuberculosis, Multidrug-Resistant
- Mycobacterium tuberculosis
- Drug Therapy, Combination
- Clofazimine
- Adult
- Isoniazid
- Child
Veja também
Estudos relacionados
- Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)
- Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment
- Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
- Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial